ARCUTIS BIOTHERAPEUTICS, INC. Common Stock, Capital Shares Reserved for Future Issuance
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) had Common Stock, Capital Shares Reserved for Future Issuance of 22.33 million shares as of 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2024-02-27
- 2023-12-31: Common Stock, Capital Shares Reserved for Future Issuance 22.33M shares.
- 2023-09-30: Common Stock, Capital Shares Reserved for Future Issuance 15.08M shares.
- 2023-06-30: Common Stock, Capital Shares Reserved for Future Issuance 15.30M shares.
- 2023-03-31: Common Stock, Capital Shares Reserved for Future Issuance 15.57M shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance |
|---|---|
| 2023-12-31 | 22.33M shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 15.08M shares 10-Q · filed 2023-11-03 |
| 2023-06-30 | 15.30M shares 10-Q · filed 2023-08-08 |
| 2023-03-31 | 15.57M shares 10-Q · filed 2023-05-09 |
| 2022-12-31 | 12.84M shares 10-K · filed 2024-02-27 |
| 2022-09-30 | 11.46M shares 10-Q · filed 2022-11-08 |
| 2022-06-30 | 11.61M shares 10-Q · filed 2022-08-04 |
| 2022-03-31 | 11.75M shares 10-Q · filed 2022-05-05 |
| 2021-12-31 | 8.16M shares 10-K · filed 2023-02-28 |
| 2021-09-30 | 8.24M shares 10-Q · filed 2021-11-04 |
| 2021-06-30 | 8.28M shares 10-Q · filed 2021-08-05 |
| 2021-03-31 | 8.36M shares 10-Q · filed 2021-05-06 |
| 2020-12-31 | 6.32M shares 10-K · filed 2022-02-22 |
| 2020-09-30 | 6.38M shares 10-Q · filed 2020-11-05 |
| 2020-06-30 | 6.41M shares 10-Q · filed 2020-08-11 |
| 2020-03-31 | 6.44M shares 10-Q · filed 2020-05-12 |
| 2019-12-31 | 28.45M shares 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |